N4 Pharma Plc

N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.

Nuvec® is currently in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems.

Sign up to our mailing list below to stay on top of all news.

Home

Regulatory news

Leadership team

Our business

About Us

Updates

AIM Rule 26

Investors Home

Investors

Open Sans

Investor information

Latest news and updates